Robert Yang - Elevation Oncology Senior Counsel

Elevation Oncology Management Efficiency

The company has return on total asset (ROA) of (0.2546) % which means that it has lost $0.2546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6367) %, meaning that it created substantial loss on money invested by shareholders. Elevation Oncology's management efficiency ratios could be used to measure how well Elevation Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. At this time, Elevation Oncology's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 1.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 2.7 M in 2024.

Similar Executives

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. Elevation Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people. Elevation Oncology (ELEV) is traded on NASDAQ Exchange in USA. It is located in 101 Federal Street, Boston, MA, United States, 02110 and employs 29 people. Elevation Oncology is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Elevation Oncology Leadership Team

Elevation Stock Performance Indicators

Additional Tools for Elevation Stock Analysis